Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G I Shapiro

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 14, 2019
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001A T Shaw, G J Riely, Y-J Bang, et al.
ESMO Open|May 13, 2025
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerM A Gouda, M H Voss, H Tawbi, et al.
Oncogene|February 22, 2007
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272Y Minami, T Shimamura, K Shah, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsA Italiano, J R Infante, G I Shapiro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancerA G Waks, O Cohen, B Kochupurakkal, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 14, 2019
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001A T Shaw, G J Riely, Y-J Bang, et al.
ESMO Open|May 13, 2025
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerM A Gouda, M H Voss, H Tawbi, et al.
Oncogene|February 22, 2007
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272Y Minami, T Shimamura, K Shah, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsA Italiano, J R Infante, G I Shapiro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancerA G Waks, O Cohen, B Kochupurakkal, et al.
Pageof 3